In the era of JAK2 inhibitors, this finding opens new possibilities for combined therapeutic targets (JAK2 inhibitors and histone posttranslational modificators) that may benefit patients with MPN [26]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.